Asia-Pacific Nuclear Medicine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Asia-Pacific Nuclear Medicine Market is segmented by Products (Diagnostics (Single Photon Emission Computed Tomography (SPECT), and Positron Emission Tomography (PET)) and Therapeutics (Alpha Emitters, Beta Emitters and Brachytherapy), Applications (Cardiology, Neurology, Oncology and Other Applications), and Geography (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific). The report offers the value (in USD million) for the above segments.

Asia-Pacific Nuclear Medicine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Asia-Pacific Nuclear Medicine Industry Overview

There is moderate competition among the players in the Asia-Pacific Nuclear Medicine market. However, this competition is not by competitive pricing or product differentiation. Additionally, big players in the pharmaceutical and biotechnology industries are leveraging their vast capital reserves to venture into this market, further increasing the competition. It is expected that in the coming years, a few small to mid-sized companies will penetrate the market and hold a substantial share in the Asia-Pacific region. Some of the companies in the market are Cardinal Health, Curium, Lantheus Medical Imaging, Inc., GE Healthcare, and Bracco Diagnostic Inc.

Asia-Pacific Nuclear Medicine Market Leaders

  1. Cardinal Health

  2. Curium SAS

  3. Lantheus Medical Imaging

  4. GE Healthcare

  5. Bracco Diagnostic Inc..

  6. *Disclaimer: Major Players sorted in no particular order
Asia-Pacific Nuclear Medicine Market Concentration

APAC Nuclear Medicine Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?